New Protein-Like Polymers Target, Degrade “Undruggable” Proteins Driving Cancer

Why It Matters

By converting elusive cancer drivers into degradable substrates, HYDRACs could unlock therapeutic strategies for a broad class of targets that have resisted conventional drug design, reshaping oncology and beyond.

Key Takeaways

• HYDRAC polymers degrade MYC without binding pockets
• KRAS degradation works across multiple mutant alleles
• Polymers recruit cellular quality‑control via degron motifs
• Tumor accumulation reduces proliferation in mouse models
• Platform may extend to neurodegenerative and inflammatory targets

Pulse Analysis

The rise of targeted protein degradation (TPD) has already begun to rewrite the rules of drug discovery, yet many high‑impact disease drivers remain out of reach because they lack druggable pockets. Traditional small‑molecule degraders such as PROTACs rely on precise ligand interactions, limiting their scope to a subset of proteins. Northwestern’s HYDRAC technology sidesteps this constraint by employing protein‑like polymers that present multiple binding motifs, enabling them to latch onto intrinsically disordered or shallow‑surface proteins like MYC and KRAS. This polymeric approach expands the TPD toolbox, offering a chemistry‑driven solution where conventional ligands falter.

Mechanistically, each HYDRAC molecule functions as a bifunctional bridge: one arm displays peptide sequences that recognize the target protein, while the opposite arm carries a degron that engages the cell’s ubiquitin‑proteasome system. The multivalent design enhances binding avidity and ensures efficient recruitment of the degradation machinery, even when the target mutates. In cell culture, HYDRACs achieved selective depletion of MYC and KRAS, suppressing downstream transcriptional programs and triggering apoptosis. Mouse studies demonstrated tumor‑localized polymer accumulation, reduced cellular proliferation, and measurable tumor‑growth inhibition, suggesting that the platform can translate in vivo efficacy without extensive off‑target effects.

Looking ahead, the modular nature of HYDRACs positions them for rapid reprogramming against a spectrum of pathogenic proteins beyond oncology, including those implicated in neurodegeneration, inflammation, and metabolic disorders. Commercialization will hinge on scaling polymer synthesis, confirming safety profiles, and integrating with existing delivery technologies. If these hurdles are cleared, HYDRACs could catalyze a new wave of therapeutics that eliminate disease‑causing proteins outright, fundamentally altering the landscape of precision medicine.